OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101)

BACKGROUND: Progression-free survival, but not overall survival, was prolonged in the experimental treatment arm with bevacizumab and lomustine (BEV/LOM) compared to the lomustine only control (LOM) arm of randomized EORTC 26101. Secondary outcomes, such as Health-Related Quality of Life (HRQoL), ar...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Taphoorn, M. J. B., Bottomley, A., Coens, C., Reijneveld, J. C., Gorlia, T., Brandes, A. A., Domont, J., Idbaih, A., van den Bent, M. J., Wick, W.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2016
Предметы:
OS5 Glioma: Clinical
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782536/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.036
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы